Editas Medicine to Present New Data Demonstrating Advancements for Translating CRISPR Technologies into Medicines at the American Society of Gene & Cell Therapy Annual Meeting
April 24, 2017 14:17 ET
|
Editas Medicine
Oral presentation of first achievement of in vivo retinal gene editing in non-human primates Oral presentation of results demonstrating the potential of CRISPR/Cas9 gene editing to treat sickle cell...
Editas Medicine, Inc. Announces Pricing of $90 Million Offering of Common Stock
March 16, 2017 21:04 ET
|
Editas Medicine
CAMBRIDGE, Mass., March 16, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the pricing of an underwritten offering of 4,000,000...
Editas Medicine, Inc., Announces Proposed Offering of Common Stock
March 15, 2017 16:14 ET
|
Editas Medicine
CAMBRIDGE, Mass., March 15, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it intends to offer and sell 4,000,000 shares of...
Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing Medicines for Eye Diseases
March 14, 2017 08:00 ET
|
Editas Medicine; Allergan plc
– Brings Together Eye Care and CRISPR Innovators to Develop Transformative Medicines for Patients – – Provides Allergan Exclusive Access to Multiple Editas Medicine Ocular Programs Based on its...
Editas Medicine Announces Fourth Quarter and Full Year 2016 Results and Update
March 07, 2017 16:01 ET
|
Editas Medicine
Recent, highly favorable U.S. Patent and Trademark Office decision affirms and upholds fundamental CRISPR/Cas9 issued patents Extended CRISPR technology leadership with addition of novel and...
Editas Medicine Announces Departure of Chief Operating Officer
March 03, 2017 09:00 ET
|
Editas Medicine
CAMBRIDGE, Mass., March 03, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that its Chief Operating Officer, Alexandra Glucksmann,...
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2016 Corporate Update and Results
February 28, 2017 16:01 ET
|
Editas Medicine
CAMBRIDGE, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday,...
Editas Medicine Joins Global Movement to Raise Awareness on Rare Disease Day 2017
February 28, 2017 08:00 ET
|
Editas Medicine
CAMBRIDGE, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced the company has joined forces with 30 million Americans and...
Editas Medicine to Present at Investor Conferences in March
February 27, 2017 16:01 ET
|
Editas Medicine
CAMBRIDGE, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor...
Editas Medicine Announces U.S. Patent and Trademark Office Decision Favorable to Broad Institute in CRISPR Interference
February 15, 2017 13:58 ET
|
Editas Medicine
CAMBRIDGE, Mass., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT) announced today that the U.S. Patent and Trademark Office (USPTO) issued a favorable decision in the CRISPR...